The effects of artesunate on the expression of EGFR and ABCG2 in A549 human lung cancer cells and a xenograft model

Molecules

Volumn 16, Issue 12, 2011, Pages 10556-10569

  Ma, Hu ^a,b   Yao, Quan ^a   Zhang, An Mei ^a   Lin, Sheng ^a   Wang, Xin Xin ^a   Wu, Lei ^a   Sun, Jian Guo ^a   Chen, Zheng Tang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

Author keywords

ABCG2; Akt; Artesunate; EGFR; Multi drug resistance; NSCLC

Indexed keywords

ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ARTEMISININ DERIVATIVE; ARTESUNATE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; PROTEIN KINASE B; TUMOR PROTEIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL DEATH; CELL PROLIFERATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; ARTEMISININS; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, NON-SMALL-CELL LUNG; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84555189779     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules161210556     Document Type: Article

References (37)

1. Schiller, J.H.; David, H.; Belani, C.P.; Corey, L.; Alan, S.; James, K.; Zhu, J.M.; David, H.J. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346, 92-98. (Pubitemid 34438899)
2. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J. Clin. Oncol. 2003, 21, 2237-2246. (Pubitemid 46621858)
3. Sequist, L.V.; Bell, D.W.; Lynch, T.J.; Haber, D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J. Clin. Oncol. 2007, 25, 587-595. (Pubitemid 350002967)
4. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Jeffrey, G.; Supko, J.G.; Haluska, F.G.; et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350, 2129-2139. (Pubitemid 38637993)
5. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman, N.; Boggon, T.J.; et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004, 304, 1497-1500. (Pubitemid 38720929)
6. Litman, T.; Druley, T.E.; Stein, W.D.; Bates, S.E. From MDR to MXR: New understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol. Life Sci. 2001, 58, 931-959. (Pubitemid 32652819)
7. Haimeur, A.; Conseil, G.; Deeley, R.G.; Cole, S.P. The MRP related and BCRP/ABCG2 multidrug resistance proteins: Biology, substrate specificity and regulation. Curr. Drug Metab. 2004, 5, 21-53. (Pubitemid 38294344)
8. Sarkadi, B.; Laczka, C.O.; Nemet, K.; Varadi, A. ABCG2-A transporter for all seasons. FEBS Lett. 2004, 567, 116-120.
9. Fisher, G.A.; Lum, B.L.; Hausdorff, J.; Sikic, B.I. Pharmacological considerations in the modulation of multidrug resistance. Eur. J. Cancer 1996, 32A, 1082-1088.
10. Bakos, E.; Evers, R.; Sinko, E.; Radi, A.S.; Borst, P.; Sarkadi, B.Z. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol. Pharmacol. 2000, 57, 760-768. (Pubitemid 30183717)
11. Ross, D.D.; Karp, J.E.; Chen, T.T.; Doyle, L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 2000, 96, 365-368. (Pubitemid 30456496)
12. Brangi, M.; Litman, T.; Ciotti, M.; Nishiyama, K.; Kohlhagen, G.; Takimoto, C.; Robey, R.; Pommier, Y.; Fojo, T.; Bates, S.E. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999, 59, 5938-5946. (Pubitemid 30004955)
13. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.M.; Rishi, A.K.; Ross, D.D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15665-15670. (Pubitemid 29018757)
14. Allen, J.D.; Schinkel, A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol. Cancer Ther. 2002, 1, 427-434.
15. Elkind, N.B.; Szentpétery, Z.; Apáti, A.; Laczka, C.O.; Várady, G.; Ujhelly, O.; Szabó, K.; Homolya, L.; Váradi, A.; Buday, L.; et al. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005, 65, 1770-1777. (Pubitemid 40478603)
16. Haura, E.B.; Tanvetyanon, T.; Chiappori, A.; Williams, C.; Simon, G.; Antonia, S.; Gray, J.; Litschauer, S.; Tetteh, L.; Neuger, A. et al. Phase I/II study of the Src inhibitor Dasatinib in combination with Erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 2010, 28, 1387-1394.
17. Berger, T.G.; Dieckmann, D.; Efferth T.; Schultz, E.S.; Funk, J.O.; Bau, A.; Schuler, G. Artesunate in the treatment of metastatic uveal melanoma-First experiences. Oncol. Rep. 2005, 14, 1599-1603.
18. Meshnick, S.R.; Yang, Y.Z.; Lima, V.; Kuypers, F.; Kamchonwongpaisan, S.; Yuthavong, Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents Chemother. 1993, 37, 1108-1114. (Pubitemid 23141328)
19. Xu, H.; He, Y.; Yang, X.; Liang, L.; Zhan, Z.; Ye, Y.; Yang, X.; Lian, F.; Sun, L. Anti-malarial agent artesunate inhibits TNF-alphainduced production of proinflammatory cytokines via inhibition of NF-kappaB and PI3 kinase/Akt signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes. Rheumatology 2007, 46, 920-926. (Pubitemid 47062496)
20. Rasheed, S.A.; Efferth, T.; Asangani, I.A.; Allgayer, H. First evidence that the antimalarial drug Artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases. Int. J. Cancer 2010, 127, 1475-1485.
21. Li, S.; Xue, F.; Cheng, Z.; Yang, X.; Wang, S.; Geng, F.; Pan, L. Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65. Int. J. Hematol. 2009, 90, 513-521.
22. Hou, J.; Wang, D.; Zhang, R.; Wang, H. Experimental therapy of hepatoma with artemisinin and its derivatives: In vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin. Cancer Res. 2008, 14, 519-5530.
23. Miao, L.Y.; Zhang, Z.Y. Reversal effect of artesunate on the multidrug-resistance of human leukemia K562/A02 cells. J. Southeast Univ. 2006, 25, 445-447.
24. Hynes, N.E.; Lane, H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5, 341-354. (Pubitemid 40637826)
25. Citri, A.; Yarden, Y. EGF-ERBB signaling: Towards the systems level. Nat. Rev. Mol. Cell Biol. 2006, 7, 505-516. (Pubitemid 44036456)
26. Alaoui-Jamali, M.A.; He, Q. The interface between ErbB and non-ErbB receptors in tumor invasion: Clinical implications and opportunities for target discovery. Drug Resist. Update. 2003, 6, 95-107. (Pubitemid 36565768)
27. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 1995, 19, 183-232.
28. Gottesman, M.M.; Fojo, T.; Bates, S.E. Multidrug resistance in cancer: Role of ATP dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58. (Pubitemid 37328807)
29. Hirschmann-Jax, C.; Foster, A.E.; Wulf, G.G.; Nuchtern, J.G.; Jax, T.W.; Gobel, U.; Goodell, M.A.; Brenner, M.K. A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. USA 2004, 101, 14228-14233. (Pubitemid 39305058)
30. Rabindran, S.K.; Ross, D.D.; Doyle, L.A.; Yang, W.; Greenberger, L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res. 2000, 60, 47-50. (Pubitemid 30058728)
31. Yin, L.; Castagnino, P.; Assoian, R.K. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. Cancer Res. 2008, 68, 800-807. (Pubitemid 351206757)
32. Evseenko, D.A.; Paxton, J.W.; Keelan, J.A. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Dispos. 2007, 35, 595-601. (Pubitemid 46513262)
33. Mogi, M.; Yang, J.; Lambert, J.F.; Colvin, G.A.; Shiojima, I.; Skurk, C.; Summer, R.; Fine, A.; Quesenberry, P.J.; Walsh, K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. J. Biol. Chem. 2003, 278, 39068-39075. (Pubitemid 37221810)
34. Takada, T.; Suzuki, H.; Gotoh, Y.; Sugiyama, Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. Drug Metab. Dispos. 2005, 33, 905-909. (Pubitemid 41002770)
35. Sertel, S.; Eichhornb, T.; Sieberb, S.; Sauerc, A.; Weissc, J.; Plinkerta, P.K.; Efferth, T. Factors determining sensitivity or resistance of tumor cell lines towards artesunate. Chem.-Biol. Interact. 2010, 185, 42-52.
36. Liu, W.M. Enhancing the cytotoxic activity of novel targeted therapies-Is there a role for a combinatorial approach? Curr. Clin. Pharmacol. 2008, 3, 108-117.
37. Liu, WM; Gravett, A.M.; Dalgleish, A.G. The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies. Int. J. Cancer 2011, 128, 1471-1480.